Comparison of Time-action Profiles of Insulin Glargine and NPH Insulin in Normal and Diabetic Dogs

Overview

Journal Vet Res Commun

Publisher Springer

Specialty Veterinary Medicine

Date 2008 Jun 26

PMID 18575956

Citations 6

Authors

A Mori

T Sako

P Lee

T Motoike

K Iwase

Y Kanaya

H Fukuta

H Mizutani

T Arai

Affiliations

Soon will be listed here.

Abstract

Intermediate insulin injections are commonly used for glycemic control in insulin dependent diabetic dogs acting as a replacement for natural insulin. Neutral Protamin Hagedorn (NPH) insulin and insulin glargine are two types of injectable insulin preparations commonly used in humans. In our study, we investigated the time-action profiles of both aforementioned insulin preparations in normal dogs in order to determine whether co-administration of NPH and glargine would be of benefit to insulin dependent diabetic dogs as it is for humans suffering from insulin dependent diabetes. Time-action profiles of NPH insulin and insulin glargine in normal dogs demonstrated a clear difference between both insulin preparations confirming that NPH insulin is an intermediate-acting preparation whereas insulin glargine is a long-lasting preparation. In addition, co-administration of NPH insulin and insulin glargine resulted in tight glycemic control as compared to NPH insulin alone in insulin dependent diabetic dogs. However, co-administration result in hypoglycemia at the dosages tested.

Citing Articles

Insulins for the long term management of diabetes mellitus in dogs: a review.

Shiel R, Mooney C Canine Med Genet. 2022; 9(1):1.

PMID: 35152907 PMC: 8842735. DOI: 10.1186/s40575-022-00114-9.

Comparison of Insulins Glargine and Degludec in Diabetic Rhesus Macaques () with CGM Devices.

Puglisi S, Mackiewicz A, Ardeshir A, Garzel L, Christe K Comp Med. 2021; 71(3):247-255.

PMID: 34034855 PMC: 8223866. DOI: 10.30802/AALAS-CM-20-000075.

The effect of Insulin Degludec on glycemic control in diabetic cats over a 12-month period.

Oda H, Mori A, Sako T J Vet Med Sci. 2020; 82(6):695-698.

PMID: 32307342 PMC: 7324837. DOI: 10.1292/jvms.19-0309.

Time-action profiles of insulin degludec in healthy dogs and its effects on glycemic control in diabetic dogs.

Oda H, Mori A, Ishii S, Shono S, Onozawa E, Sako T J Vet Med Sci. 2018; 80(11):1720-1723.

PMID: 30305465 PMC: 6261804. DOI: 10.1292/jvms.17-0714.

Supplementing transglucosidase with a high-fiber diet for prevention of postprandial hyperglycemia in streptozotocin-induced diabetic dogs.

Sako T, Mori A, Lee P, Goto H, Fukuta H, Oda H Vet Res Commun. 2010; 34(2):161-72.

PMID: 20165914 DOI: 10.1007/s11259-010-9342-0.

References

Nathan D, Genuth S, Lachin J, Cleary P, Crofford O, Davis M . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-86. DOI: 10.1056/NEJM199309303291401. View

Heise T, Nosek L, Ronn B, Endahl L, Heinemann L, Kapitza C . Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004; 53(6):1614-20. DOI: 10.2337/diabetes.53.6.1614. View

Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T . Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care. 2000; 23(5):644-9. DOI: 10.2337/diacare.23.5.644. View

Lepore M, Pampanelli S, Fanelli C, Porcellati F, Bartocci L, Di Vincenzo A . Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000; 49(12):2142-8. DOI: 10.2337/diabetes.49.12.2142. View

Rave K, Nosek L, Heinemann L, Frick A, Becker R . Time-action profile of the long-acting insulin analogue insulin glargine in comparison to NPH insulin in Japanese volunteers. Diabetes Metab. 2003; 29(4 Pt 1):430-1. DOI: 10.1016/s1262-3636(07)70055-1. View